Flanders University researchers have found in the Sleep Apnea Cardiovascular Endpoints (SAVE) trial that a CPAP treatment leads to a decrease in depression cases with cardiovascular patients.
Led in Australia, the largest trial of its type and one of a few with this focus, Flanders University found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular disease.
Key Points to the Study
- SAVE trial participants recruited from more than 80 clinical centers in China, Australia, New Zealand, India and the USA, Spain and Brazil and were predominantly overweight and older makes, habitual snorers and had moderately severe OSA.
- The latest study revealed a significant fall in depression symptoms in OSA patients after CPAP treatment, independent of improvements in daytime sleepiness.
- The positive effect of CPAP treatment on depression symptoms was manifest within six months after persisted during the 3.7 years of follow up.
- The positive effect of CPAP treatment on depression symptoms was more pronounced in patients with lower mood scores prior to treatment.
Professor Doug McEvoy, Flanders University